Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trialLancet Diabetes Endocrinol 2023 Mar 03;[EPub Ahead of Print], M Schechter, SD Wiviott, I Raz, EL Goodrich, A Rozenberg, I Yanuv, SA Murphy, TA Zelniker, M Fredriksson, PA Johansson, LA Leiter, DL Bhatt, DK McGuire, JPH Wilding, IAM Gause-Nilsson, A Cahn, AM Langkilde, MS Sabatine, O Mosenzon
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.